查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1443368

降膽固醇藥物市場，按藥物類別、按疾病類型、按配銷通路、按國家和地區分類 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Cholesterol-lowering Drug Market, By Drug class, By Disease type, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2023年降膽固醇藥物市場規模為1,840,087萬美元，2024年至2032年複合CAGR為3.4%。

降膽固醇藥物市場-市場動態

提高對高膽固醇不利影響的認知以推動市場需求

由於人們對高膽固醇不良影響的認知不斷提高，全球降膽固醇藥物市場正經歷顯著成長。這種成長促使製造商進行廣泛的調查研究，以確定耐受性良好的藥物，以改善患者的治療結果。此外，該行業強勁的研發活動，以及用於開發新藥的 bempedoic 酸的加入，都有助於市場的成長。迎合非他汀類藥物使用者的新藥物類別的出現正在推動市場成長。然而，他汀類藥物使用者數量的不斷增加以及各種指南對降血脂藥採用的認可進一步推動了市場的擴張。膽固醇水平升高會增加中風和心肌梗塞的風險，而高膽固醇血症則與心血管疾病 (CVD) 以及慢性腎臟病和 2 型糖尿病等合併症的易感性增加有關。這些因素是市場成長的額外驅動力。 Bempedoic Acid、PCSK9抑制劑和其他藥物等療法的推出預計將有助於市場的持續擴張。

降膽固醇藥物市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 3.4% 左右的CAGR成長

根據藥物類別細分，預計他汀類藥物將在 2023 年佔據最大市場佔有率

根據疾病類型細分，2023年高膽固醇血症為主導類型

按地區分類，北美是 2023 年的主要收入來源

降膽固醇藥物市場-細分分析：

全球降膽固醇藥物市場根據藥物類別、疾病類型、配銷通路和地區進行細分。

市場依藥物類別分為五大類：合併用藥、PCSK9抑制劑、膽固醇吸收抑制劑、膽汁酸螯合劑和他汀類藥物。他汀類藥物佔據了全球降膽固醇藥物市場的最大佔有率，這主要是由於 Bempedoic Acid 和 PCSK9 抑制劑等有效療法的推出。

市場依疾病類型分為四類：高膽固醇血症、心血管疾病、高血脂、其他。在降膽固醇藥物市場的疾病類型中，高膽固醇血症是一個主要焦點。高膽固醇血症以血液中膽固醇水平升高為特徵，由於其與心血管疾病密切相關，因此是降膽固醇藥物的主要目標。作為動脈粥狀硬化的關鍵因素，高膽固醇血症是心臟相關疾病的重要危險因子。因此，製藥公司大力投資開發和行銷藥物，例如他汀類藥物和 PCSK9 抑制劑，專門用於解決高膽固醇血症和降低心血管事件的風險。高膽固醇血症在全球的流行凸顯了其在塑造降膽固醇藥物開發模式和市場趨勢的主導地位。

降膽固醇藥物市場-地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太地區以及中東和非洲地區。這些區域根據開展業務的國家進一步分類。

降膽固醇藥物市場-競爭格局：

降膽固醇藥物市場的公司正在策略性地引領心血管健康和個人化醫療不斷發展的格局。正在進行的研究和開發工作重點是發現新的治療標靶以及開發具有更高療效和更少副作用的下一代降膽固醇藥物。與醫療保健提供者、研究機構和監管機構的策略合作有助於進行臨床試驗並獲得新藥物配方的市場批准。此外，也進行教育活動和宣傳活動，以強調膽固醇管理的重要性以及這些藥物在預防心血管事件中的作用。隨著市場轉向個人化治療方法，公司正在投資精準醫療策略，探索遺傳因素，並利用創新技術根據個別患者的需求量身訂做降膽固醇療法。降膽固醇藥物市場仍然是全球對抗心血管疾病和改善整體心臟健康努力不可或缺的一部分。

最近的發展：

2021 年，Inclisiran 獲得 NHS 批准使用，臨床試驗證明其能夠降低約 50% 的 LDL 膽固醇水平。據英國 NHS 稱，以 Leqvio 品牌銷售的 Inclisiran 有可能避免 55,000 例心臟病和中風，到 2031 年估計可挽救 30,000 人的生命。

目錄

第1章：降膽固醇藥物市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按藥物類別分類的降膽固醇藥物市場片段
    • 按疾病類型分類的降膽固醇藥物市場片段
    • 按配銷通路分類的降膽固醇藥物市場片段
    • 按國家/地區分類的降膽固醇藥物市場摘要
    • 按地區分類的降膽固醇藥物市場片段
  • 競爭洞察

第 3 章：降膽固醇藥物主要市場趨勢

  • 降膽固醇藥物市場促進因素
    • 市場促進因素的影響分析
  • 降膽固醇藥物市場限制
    • 市場限制影響分析
  • 降膽固醇藥物市場機會
  • 降膽固醇藥物市場未來趨勢

第 4 章：降膽固醇藥物工業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：降膽固醇藥物市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：降膽固醇藥物市場格局

  • 2023 年降膽固醇藥物市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：降膽固醇藥物市場 - 按藥物類別

  • 概述
    • 按藥品類別分類的細分市場佔有率分析
    • 組合藥物
    • Pcsk9抑制劑
    • 膽固醇吸收抑制劑
    • 膽汁酸螯合劑
    • 他汀類藥物

第 8 章：降膽固醇藥物市場 - 按疾病類型

  • 概述
    • 按疾病類型分類的細分市場佔有率分析
    • 高膽固醇血症
    • 心血管疾病
    • 高血脂症
    • 其他

第 9 章：降膽固醇藥物市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 網路藥局
    • 零售藥局
    • 其他

第 10 章：降膽固醇藥物市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美降膽固醇藥物主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按藥物類別）
    • 北美市場規模和預測（按疾病類型）
    • 北美市場規模和預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲降膽固醇藥物主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按藥物類別）
    • 歐洲市場規模與預測（按疾病類型）
    • 歐洲市場規模和預測（按配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區降膽固醇藥物主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模和預測（按藥物類別）
    • 亞太地區市場規模與預測（按疾病類型）
    • 亞太地區市場規模和預測（按配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲降膽固醇藥物主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按藥物類別）
    • 拉丁美洲市場規模與預測（按疾病類型）
    • 拉丁美洲市場規模和預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲降膽固醇藥物主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按藥物類別）
    • 中東和非洲市場規模及預測（按疾病類型）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 降膽固醇藥物產業

  • 競爭儀表板
  • 公司簡介
    • Daiichi Sankyo
    • Merck & Co., Inc.
    • AstraZeneca
    • Esperion Therapeutics and CJ Healthcare
    • Sanofi
    • Amgen, Inc.
    • Pfizer, Inc,
    • Merck & Co., Inc.
    • AbbVie, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • GlaxoSmithKline plc.
    • Others

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: AVB2262

REPORT HIGHLIGHT

Cholesterol-lowering Drug Market size was valued at USD 18,400.87 Million in 2023, expanding at a CAGR of 3.4% from 2024 to 2032.

Cholesterol is categorized within the class of steroids, which are organic molecules and a type of lipids. It serves as a crucial structural component in the membranes of animal cells and is biosynthesized by all animal cells. The significance of cholesterol lies in its role in the biological synthesis of steroid hormones such as testosterone and estrogen, vitamin D, and bile acids. The primary sources of cholesterol production include poultry, meat, eggs, and dairy products. Elevated cholesterol levels can result from genetic diseases, obesity, an unhealthy diet, and various other medical conditions. The market for cholesterol-lowering drugs encompasses pharmaceuticals designed to decrease elevated cholesterol levels in the bloodstream, with a primary focus on reducing low-density lipoprotein (LDL) cholesterol. These drugs play a pivotal role in managing cardiovascular health by lowering the risk of atherosclerosis and related complications. As conditions like hypercholesterolemia and cardiovascular diseases become more prevalent globally, cholesterol-lowering drugs, such as statins, PCSK9 inhibitors, and bile acid sequestrants, are commonly prescribed to regulate cholesterol levels and mitigate the risk of heart-related conditions.

Cholesterol-lowering Drug Market- Market Dynamics

Increasing awareness of high cholesterol's adverse effects to propel market demand

The global Cholesterol-lowering Drug market is experiencing significant growth, driven by increasing awareness of high cholesterol's adverse effects. This growth has prompted manufacturers to conduct extensive investigational studies to identify well-tolerated drugs for improved patient outcomes. Furthermore, robust research and development activities in the sector, along with the incorporation of bempedoic acid for developing new drugs, contribute to the market's growth. The emergence of new drug classes catering to non-statin users is boosting market growth. However, the rising number of statin users and the endorsement of antihyperlipidemic adoption by various guidelines further propel market expansion. Elevated cholesterol levels increase the risks of stroke and myocardial infarction, while hypercholesterolemia is linked to increased vulnerability to cardiovascular diseases (CVD) and comorbidities like chronic kidney disease and type 2 diabetes. These factors act as additional drivers for market growth. The introduction of therapies such as bempedoic acid, PCSK9 inhibitors, and other drugs is expected to contribute to the market's continued expansion.

Cholesterol-lowering Drug Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.4% over the forecast period (2024-2032)

Based on drug class segmentation, statins was predicted to show maximum market share in the year 2023

Based on disease type segmentation, hypercholesterolemia was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Cholesterol-lowering Drug Market- Segmentation Analysis:

The Global Cholesterol-lowering Drug Market is segmented on the basis of Drug class, Disease type, Distribution Channel, and Region.

The market is divided into five categories based on drug class: combination drugs, PCSK9 inhibitors, cholesterol absorption inhibitors, bile acid sequestrants, and statins. The statins segment commands the largest portion of the global cholesterol-lowering drug market, primarily due to the introduction of effective therapies such as bempedoic acid and PCSK9 inhibitors.

The market is divided into four categories based on disease type: Hypercholesterolemia, Cardiovascular Diseases, Hyperlipidaemia, Others. Among the disease types in the cholesterol-lowering drug market, hypercholesterolemia stands out as a dominant focus. Hypercholesterolemia, characterized by elevated levels of cholesterol in the blood, is a primary target for cholesterol-lowering drugs due to its strong association with cardiovascular diseases. As a key contributor to atherosclerosis, hypercholesterolemia is a significant risk factor for heart-related conditions. Consequently, pharmaceutical companies are heavily invested in developing and marketing drugs, such as statins and PCSK9 inhibitors, specifically tailored to address hypercholesterolemia and mitigate the risk of cardiovascular events. The prevalence of hypercholesterolemia worldwide underscores its dominance in shaping the landscape of cholesterol-lowering drug development and market trends.

Cholesterol-lowering Drug Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Cholesterol-lowering Drug Market- Competitive Landscape:

Companies in the cholesterol-lowering drug market are strategically navigating the evolving landscape of cardiovascular health and personalized medicine. Ongoing research and development efforts focus on the discovery of novel therapeutic targets and the development of next-generation cholesterol-lowering drugs with improved efficacy and fewer side effects. Strategic collaborations with healthcare providers, research institutions, and regulatory bodies aid in conducting clinical trials and gaining market approvals for new drug formulations. Additionally, educational initiatives and awareness campaigns are undertaken to highlight the importance of cholesterol management and the role of these drugs in preventing cardiovascular events. As the market shifts towards personalized treatment approaches, companies are investing in precision medicine strategies, exploring genetic factors, and leveraging innovative technologies to tailor cholesterol-lowering therapies for individual patient needs. The cholesterol-lowering drug market remains integral to global efforts in combating cardiovascular diseases and improving overall heart health.

Recent Developments:

In 2021, Inclisiran received approval for NHS use following clinical trials that demonstrated its ability to reduce LDL cholesterol levels by approximately 50%. According to NHS England, Inclisiran, marketed under the brand name Leqvio, has the potential to avert 55,000 heart attacks and strokes, leading to an estimated 30,000 lives saved by the year 2031.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Daiichi Sankyo

Merck & Co., Inc.

AstraZeneca

Esperion Therapeutics and CJ Healthcare

Sanofi

Amgen, Inc.

Pfizer, Inc,

Merck & Co., Inc.

AbbVie, Inc.

Sun Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Company Limited

Novartis AG

GlaxoSmithKline plc.

Others

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Combination drugs
  • Pcsk9 inhibitors
  • Cholesterol absorption inhibitors
  • Bile acid sequestrants
  • Statins

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Hypercholesterolemia
  • Cardiovascular Diseases
  • Hyperlipidaemia
  • Others

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Others

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cholesterol-lowering Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cholesterol-lowering Drug Market Snippet by Drug class
    • 2.1.2. Cholesterol-lowering Drug Market Snippet by Disease type
    • 2.1.3. Cholesterol-lowering Drug Market Snippet by Distribution channel
    • 2.1.4. Cholesterol-lowering Drug Market Snippet by Country
    • 2.1.5. Cholesterol-lowering Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Cholesterol-lowering Drug Key Market Trends

  • 3.1. Cholesterol-lowering Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cholesterol-lowering Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cholesterol-lowering Drug Market Opportunities
  • 3.4. Cholesterol-lowering Drug Market Future Trends

4. Cholesterol-lowering Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cholesterol-lowering Drug Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Cholesterol-lowering Drug Market Landscape

  • 6.1. Cholesterol-lowering Drug Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cholesterol-lowering Drug Market - By Drug class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug class, 2023 & 2032 (%)
    • 7.1.2. Combination drugs
    • 7.1.3. Pcsk9 inhibitors
    • 7.1.4. Cholesterol absorption inhibitors
    • 7.1.5. Bile acid sequestrants
    • 7.1.6. Statins

8. Cholesterol-lowering Drug Market - By Disease type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease type, 2023 & 2032 (%)
    • 8.1.2. Hypercholesterolemia
    • 8.1.3. Cardiovascular Diseases
    • 8.1.4. Hyperlipidaemia
    • 8.1.5. Others

9. Cholesterol-lowering Drug Market - By Distribution channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Online Pharmacies
    • 9.1.4. Retail Pharmacies
    • 9.1.5. Others

10. Cholesterol-lowering Drug Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Cholesterol-lowering Drug Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Cholesterol-lowering Drug Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Cholesterol-lowering Drug Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Cholesterol-lowering Drug Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Cholesterol-lowering Drug Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Cholesterol-lowering Drug Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Daiichi Sankyo
    • 11.2.2. Merck & Co., Inc.
    • 11.2.3. AstraZeneca
    • 11.2.4. Esperion Therapeutics and CJ Healthcare
    • 11.2.5. Sanofi
    • 11.2.6. Amgen, Inc.
    • 11.2.7. Pfizer, Inc,
    • 11.2.8. Merck & Co., Inc.
    • 11.2.9. AbbVie, Inc.
    • 11.2.10. Sun Pharmaceutical Industries Ltd.
    • 11.2.11. Takeda Pharmaceutical Company Limited
    • 11.2.12. Novartis AG
    • 11.2.13. GlaxoSmithKline plc.
    • 11.2.14. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Cholesterol-lowering Drug Market: Drug class Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Drug class
  • TABLE Global Cholesterol-lowering Drug Market, by Drug class 2019-2032 (USD Million)
  • TABLE Cholesterol-lowering Drug Market: Disease type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Disease type
  • TABLE Global Cholesterol-lowering Drug Market, by Disease type 2019-2032 (USD Million)
  • TABLE Cholesterol-lowering Drug Market: Distribution channel Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution channel
  • TABLE Global Cholesterol-lowering Drug Market, by Distribution channel 2019-2032 (USD Million)
  • TABLE Cholesterol-lowering Drug Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Cholesterol-lowering Drug Market, by Region 2019-2032 (USD Million)
  • TABLE North America Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE North America Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE North America Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)
  • TABLE Europe Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE Europe Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE Europe Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)
  • TABLE Asia Pacific Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE Asia Pacific Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)
  • TABLE Latin America Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE Latin America Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE Latin America Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)